TrialBMC infectious diseases2025
Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.
Liwei Shi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.